Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 20

08:13 EST 23rd November 2017 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 476–500 of 7,700+

Probably Relevant

Realm Therapeutics to initiate Phase II trial for allergic conjunctivitis

Realm Therapeutics is set to initiate a Phase II clinical trial of PR013 to treat allergic conjunctivitis (AC), following approval of its investigational new drug (IND) application by the US Food and Drug Administration (FDA).


Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma

Wednesday, August 23rd 2017 at 12:00pm UTC – First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics – – Company Plans to Initiate Patient Dosing in a Multi-center, Phase 1 Trial in Q1 2018 – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Unum Therapeutics Inc., a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to trea...

PTC Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 16102017] Prices from USD $350

PTC Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's PTC Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken...


PTC Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 14062017] Prices from USD $350

PTC Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's PTC Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken...

Stand Up to “Bully” Trump: Bio CEOs Levin, Holtzman Call to Their Peers

Biotech CEOs Jeremy Levin and Steve Holtzman have watched the violence in Charlottesville, VA, and its continuing aftermath with disgust. But they aren’t just upset about the rally, the violence and death, and President Trump’s equivocating blame of “many sides.” Levin, of Ovid Therapeutics (NASDAQ: OVID), and Holtzman, of Decibel Therapeutics, have been disappointed with […]

Spark Therapeutics announces public offering of common stock

Spark Therapeutics will offer $300 million in shares of common stock, according to a company press release.Underwriters will be granted an option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price for a period of 30 days, the release said.

Advanced Proteome Therapeutics to Attend 2017 BIO-Europe Conference to Discuss Partnership Initiatives with Leading Biotechnology Companies

VANCOUVER, BC--(Marketwired - November 06, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics, will be attending the 2017 BIO-Europe 2017 Conference from November 6-8, 2017 at the CityCube, Berlin, Germany. Advanced Proteome Therapeutics will be meetin...

FDA Confirms Amicus Therapeutics May Submit New Drug Application for Migalastat for Fabry Disease

CRANBURY, N.J., July 11, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) plans to submit a new drug application (NDA) to the U.S. FDA for the oral precision medicine migalastat for Fabry disease in the fourth quarter of 2017. Based on a...

FDA approves first generic from Vitruvias Therapeutics, Sunny Pharmtech

David SalazarSILVER SPRING, Md. — The Food and Drug Administration has approved the first generic from Taiwan-based drug development company Sunny Pharmtech and generic development company Vitruvias Therapeutics. The companies announced the approval of its generic lidocaine ointment, 5%.read more

Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at the Canaccord Genuity 37th Annual Growth Conference in Boston, MA on Wednesday, August 9 at 1:00 p.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will beco...

Synthetic Human-Derived Peptides and Peptidomimetics for Cancer Therapeutics

FDA approved 26S proteasome inhibitors, such as carfilzomib and bortezomib (Velcade®) have proven to be effective at treating hematologic cancers. However, resistance to these agents as well as their toxicity have raised concerns and highlight the need for new 26S proteasome inhibitors.Read more about Synthetic Human-Derived Peptides and Peptidomimetics for Cancer Therapeutics

Appointments: Novo Nordisk, Horizon Pharma, Jounce Therapeutics, Pfenex and Pharmalink

This week's roundup includes CEO appointments by ProTA and Pfenex with various other high-level appointments by Novo Nordisk, Jounce Therapeutics...   

IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results

IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.

Sigilon Therapeutics to Present at Upcoming September Conferences

CAMBRIDGE, Mass., Sept. 7, 2017 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in September. 24th Annual BioCentury NewsMakers in the Biotech Industry Conference Presenter: ...

Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis Knee Pain

BURLINGTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the...

CanniMed Therapeutics Inc. (TSX: $CMED.V) Receives License from Health Canada to Produce #MedicalCannabis Capsules

SASKATOON, Saskatchewan - October 16, 2017 (Investorideas.com Newswire) CanniMed Therapeutics Inc. (TSX: CMED) ("CanniMed") has initiated production of CanniMed Capsules, following the receipt of the Production License granted by Health Canada.

Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125...Read More... The post Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics appeared first on Drug Development Technology.

AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum

Thursday, September 21st 2017 at 11:00am UTC ALAMEDA, Calif.–(BUSINESS WIRE)– AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announces that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is participating in a fireside chat at Cell & Gene Therapy CEO on Monday, September 25, 2017 … Cet article AgeX The...

Global Blood Therapeutics Discontinues Development of Idiopathic Pulmonary Fibrosis Program

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). This decision is based on results from three proof-of-concept studies including a Phase 1 study in healthy volunteers called Basecamp and two Phase …

INSYS founder resigns from board after charges in US opioid bribe case

The billionaire founder of INSYS Therapeutics Inc John N. Kapoor, has resigned from the company's board of directors, the company said in a statement on Sunday. The billionaire founder of Insys Therapeutics Inc. John Kapoor, exits the federal court house after a bail hearing in Phoenix, Arizona , U.S., October 27, 2017.

Chroma Therapeutics’ Deal with GlaxoSmithKline

At the BIA Leadership Summit, Dr Fintan Walton spoke to Ian Nicholson, CEO of Chroma Therapeutics. They discussed: • Chroma’s deal with GSK • the key to Chroma’s novel chemistry platform technology and the importance of having a platform when running a biotech company • biotech funding and the importance of government support for the industry • how deal making has changed in the last ...

Ci Therapeutics Announces Positive Preclinical Data On Ican.Sleep Advanced Cannabinoid Formula; Anti-Insomnia Product Launch Expected In 2018

NEW YORK & JERUSALEM--(BUSINESS WIRE)--Ci Therapeutics (CIT), a CannRx/iCAN:Israel-Cannabis joint venture, is proud to announce positive breakthrough pre-clinical data on its ican.sleep program utilizing the patented CannTrap cannabis reactor platform developed by CannRx. ...

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of InVivo Therapeutics Holding Corp. - NVIV

NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Pomerantz LLP is investigating claims on behalf of investors of InVivo Therapeutics Holding Corp. ("InVivo" or the "Company") (NASDAQ: NVIV). Such invest...

Bruno Lucidi Appointed CEO of AgenTus Therapeutics

Bruno Lucidi has been named CEO of AgenTus Therapeutics, a subsidiary of Lexington, MA, cancer drug developer Agenus (NASDAQ: AGEN). AgenTus is also developing cancer treatments, but it will focus specifically on cell therapies. Lucidi’s industry experience includes senior roles at GlaxoSmithKline (NYSE: GSK), Johnson & Johnson (NYSE: JNJ), and Bristol-Myers Squibb (NYSE: BMY).

ADC Therapeutics Triggers Second Target-Specific License To Synaffix ADC Platform Under Existing Agreement

AMSTERDAM--(BUSINESS WIRE)--Synaffix BV announced today that ADC Therapeutics has triggered a second target-specific license under their Commercial License Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffixs proprietary site-specific antibody-drug conjugation technology...


Quick Search
Advertisement
 

News Quicklinks